CMS Open Payments · Program Year 2024
KARL STORZ SE & Co. KG
KARL STORZ SE & Co. KG reported $39,550.77 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 2 transactions.
- $39.6K Below-median payer
- All-tracks total
- 2 Below-median volume
- Transactions
- 2 Below-median reach
- Recipients
- #1408
- of 1,925 companies
KARL STORZ SE & Co. KG reported $39,550.77 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #1408 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $39,550.77, averaging $19.8K per recipient.
KARL STORZ SE & Co. KG's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer karl-storz-se-co-kg KARL STORZ SE & Co. KG
$39.6K · #1408/1,925 · 0.0% industry · PY2024
- TOT $39.6K
- RANK #1408
- SHARE 0.0%
- TXN 2
- RCP 2
- CAT 1
- GEN $39.6K
- TOP1 77.4%
- PY 2024
Volume peers
Nearest volume peer: Legacy Ortho LLC ($39.6K)
KARL STORZ SE & Co. KG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for KARL STORZ SE & Co. KG
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For KARL STORZ SE & Co. KG that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Royalty or License" at $39.6K, accounting for 100.0% of this company's General Payments and 2 transactions.
General Payment Breakdown by Type
"Royalty or License" leads KARL STORZ SE & Co. KG's 1-category general-payment breakdown at $39.6K, 100.0% of the reported total.
How KARL STORZ SE & Co. KG divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $39.6K | 2 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $39,550.77 (100.0%) of $39,550.77 in this company's General Payments records across 2 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for KARL STORZ SE & Co. KG
The five named recipients with the highest reported General Payments from this company
- 1
Ohsu Hospital And Clinics
$30,623.34 across 1 reported transactions
- 2
Charles H Koh
$8,927.43 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
KARL STORZ SE & Co. KG ranks #1408 of 1,925 by total payments (bottom 27% by spend) but is notably more concentrated than that alone would suggest -- #245 of 1,838 by HHI (top 13% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Epien Medical, Inc. : $7.0K total payments, HHI 6624
- Esteve Pharmaceuticals LLC : $93.5K total payments, HHI 6597
- Philadelphia Medical Management Company LLC : $174.9K total payments, HHI 6579
- Bernhard Foerster GmbH : $347.7K total payments, HHI 6541
- Helios Cardio Inc : $17.4K total payments, HHI 6534
- Instrumentation Laboratory Company : $1.4M total payments, HHI 6528
- KARL STORZ SE & Co. KG (this company) : $39.6K total payments, HHI 6505
- Novocure GmbH : $19.1K total payments, HHI 6485
- Prolaio, Inc. : $8.5K total payments, HHI 6466
- Catalent Pharma Solutions, LLC : $6.3K total payments, HHI 6454
- Dutch Ophthalmic Research Center (International) B.V. : $12.1K total payments, HHI 6407
- Sealonix Inc. : $44.9K total payments, HHI 6380
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as KARL STORZ SE & Co. KG's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about KARL STORZ SE & Co. KG.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with KARL STORZ SE & Co. KG.
Showing 6 of 1,924 companies with CMS-reported payment data.
ONY Biotech Inc.
Cadwell Industries, INC
Northgate Technologies, Inc.
Henry Schein One, LLC
GRT US Holding, Inc.
Put this to use
KARL STORZ SE & Co. KG ranks #1408 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just KARL STORZ SE & Co. KG. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.